133 related articles for article (PubMed ID: 17024766)
1. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
Rice C; Wilantewicz H
AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
[TBL] [Abstract][Full Text] [Related]
2. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
Oates E; Dzintars K
Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
[TBL] [Abstract][Full Text] [Related]
3. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives.
Horne R; Cooper V; Fisher M
AIDS Care; 2008 Oct; 20(9):1029-38. PubMed ID: 18825512
[TBL] [Abstract][Full Text] [Related]
4. Localized amyloidosis at the site of enfuvirtide injection.
Morilla ME; Kocher J; Harmaty M
Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777
[No Abstract] [Full Text] [Related]
5. Enfuvirtide and cutaneous injection-site reactions.
Mirza RA; Turiansky GW
J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
[TBL] [Abstract][Full Text] [Related]
7. Enfuvirtide: a new class of antiretroviral therapy for HIV infection.
Leao JC; Frezzini C; Porter S
Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
[TBL] [Abstract][Full Text] [Related]
9. Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact.
Glutzer E; Lalezari JP
J Assoc Nurses AIDS Care; 2005; 16(5):26-34. PubMed ID: 16433107
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
Glutzer E
AIDS Read; 2003 Mar; 13(3 Suppl):S14-6. PubMed ID: 12765161
[TBL] [Abstract][Full Text] [Related]
11. Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).
Allavena C; Prazuck T; Reliquet V; Verdon R; Perré P; Le Moal G; Billaud E; Raffi F
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):187-92. PubMed ID: 18599881
[TBL] [Abstract][Full Text] [Related]
12. Enfuvirtide (T-20): potentials and challenges.
Foy K; Juethner SN
J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
[TBL] [Abstract][Full Text] [Related]
13. [Enfuvirtide].
Gerstoft J
Ugeskr Laeger; 2004 Nov; 166(48):4355-7. PubMed ID: 15587625
[No Abstract] [Full Text] [Related]
14. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
Ball RA; Kinchelow T;
J Am Acad Dermatol; 2003 Nov; 49(5):826-31. PubMed ID: 14576660
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
True AL; Chiu YY; Demasi RA; Stout R; Patel I
Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
[TBL] [Abstract][Full Text] [Related]
16. A novel form of amyloid deposited at the site of enfuvirtide injection.
Naujokas A; Vidal CI; Mercer SE; Harp J; Kurtin PJ; Fox LP; Thompson MM
J Cutan Pathol; 2012 Feb; 39(2):220-1; quiz 219. PubMed ID: 22264247
[No Abstract] [Full Text] [Related]
17. Enfuvirtide: a novel agent for the treatment of HIV-1 infection.
Duffalo ML; James CW
Ann Pharmacother; 2003 Oct; 37(10):1448-56. PubMed ID: 14519027
[TBL] [Abstract][Full Text] [Related]
18. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS
AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302
[TBL] [Abstract][Full Text] [Related]
19. Relapse of intravenous drug use triggered by enfuvirtide, a parenteral antiretroviral medication.
Avelino-Silva VI; Li HY; Novaes CT
AIDS Patient Care STDS; 2012 Feb; 26(2):71-2. PubMed ID: 22148866
[TBL] [Abstract][Full Text] [Related]
20. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
